Trulicity leads mixed third quarter for Lilly; shares sink

Eli Lilly and Co’s diabetes drug Trulicity helped power higher-than-expected third-quarter profit on Tuesday, while sales of some other newer treatments fell short of Wall Street estimates.

…read more

Source:: Reuters – Business News

      

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.